Here’s some of HealthDay’s top stories for Thursday, Aug. 12: FDA to OK booster shot of COVID vaccine for immunocompromised people. About 3% of Americans have weakened immune systems due to various medical conditions, and the standard regimen of COVID-19 vaccines may not provide enough immunity. The FDA on ThursdayContinue Reading

WEDNESDAY, Aug. 11, 2021 (HealthDay News) — Roaring, fast-moving blazes. Choking smoke. Fiery tornados. Thunderstorms and lightning. The Dixie Fire — now the single largest wildfire in California history — continues to spread, having burned through more than 750 square miles of forest land north of Sacramento. The astonishing spreadContinue Reading

Here’s some of HealthDay’s top stories for Wednesday, Aug. 11: Experts ask Biden to boost global vaccine supply. Tens of millions of unused COVID-19 vaccines are currently in U.S. warehouses, while most people in Africa and Asia haven’t received a single dose. On Tuesday, a consortium of 175 renowned expertsContinue Reading

Here’s some of HealthDay’s top stories for Tuesday, Aug. 10: U.S. military must be vaccinated by mid-September. With U.S. COVID cases still rising, the Pentagon announced Monday that all members of the military need to get their shots by Sept. 15 or when full FDA approval of the vaccine arrives,Continue Reading

Here’s some of HealthDay’s top stories for Monday, Aug. 9: Fauci says full approval of Pfizer vaccine could come before September. Many Americans leery of getting a COVID vaccine point to its FDA ’emergency use’ status as a reason they’re unsure. Dr. Anthony Fauci says that excuse may soon beContinue Reading

Here’s some of HealthDay’s top stories for Friday, Aug. 6: Biden Administration announces new push to get kids vaccinated as schools reopen. With a new school year beginning and the Delta variant upping COVID infection rates, the White House on Thursday outlined new plans to help get children 12 andContinue Reading

Here’s some of HealthDay’s top stories for Thursday, Aug. 5: Moderna says its vaccine still strong after six months. A new report that is short on details says efficacy barely budged in that period, although it is unclear whether that data included the time since the Delta variant has dominated.Continue Reading